BridgeMD
New treatment option for Pneumonia
Official title A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.gov ID: NCT07615010
What this study is testing
What is agenT-797?
agenT-797 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for pneumonia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based...
- Acute hypoxemic respiratory failure (AHRF)
- Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria
- Onset of severe pneumonia with AHRF ≤7 days prior to informed consent Key
You likely can't join if
- More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent
- Pregnancy or breastfeeding
- History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close...
- Current participation in another treatment clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening...
The study team makes the final eligibility decision.
Where it's taking place
- San Francisco, California, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Lviv, Ukraine
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Francisco, California, United States; Houston, Texas, United States; San Antonio, Texas, United States; Lviv, Ukraine. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.